Shree Ganesh Biotech (India) Ltd (539470)
Latest quarterly results (Q1 FY27)
In its latest reported quarter, Q1 FY27, Shree Ganesh's revenue was ₹1.4 Cr (+3.6% year on year, -32.6% on the previous quarter), and net profit ₹-0.6 Cr (against a profit a year earlier); the operating margin was -62.5%.
| Q1 FY27 (₹ Cr) | Value | YoY vs Q1 FY26 | QoQ |
|---|---|---|---|
| Revenue | ₹1.4 | +3.6% | -32.6% |
| Operating profit | ₹-0.9 | loss widened | loss widened |
| Net profit | ₹-0.6 | to loss | loss widened |
| EPS (₹) | -0.01 | to loss | — |
| Operating margin | -62.5% | — | — |
📢 Recent Corporate Announcements
Shree Ganesh Biotech (India) Ltd has submitted its quarterly statement regarding the deviation or variation in the use of proceeds from public or preferential issues. The company confirmed that as of June 30, 2026, there are no unutilized funds remaining from any past fundraises, including Rights Issues or QIPs. Consequently, no deviations from the stated objects of these issues were reported. This filing is a standard regulatory requirement under SEBI Regulation 32(1).
- Zero unutilized funds reported as of the quarter ending June 30, 2026
- No deviation or variation in the use of proceeds from past public or preferential issues
- Filing complies with SEBI Circular CIR/CFD/CMD1/162/2019 dated December 24, 2019
- Statement covers all past fundraises including Rights Issues and QIPs
Shree Ganesh Biotech reported a net loss of Rs 0.57 Cr for the quarter ended June 30, 2026, a sharp reversal from a profit of Rs 0.33 Cr in the same period last year. While revenue from operations grew marginally by 3.3% YoY to Rs 1.43 Cr, it fell 32.6% sequentially from the March 2026 quarter. A critical concern is that the cost of materials consumed (Rs 1.87 Cr) exceeded the total revenue from sales (Rs 1.43 Cr), leading to negative gross margins. The company's losses have widened for the second consecutive quarter.
- Net loss of Rs 57.32 lacs in Q1 FY27 compared to a profit of Rs 32.70 lacs in Q1 FY26
- Revenue from operations declined 32.6% QoQ to Rs 142.99 lacs from Rs 212.13 lacs
- Cost of materials consumed stood at Rs 186.67 lacs, representing 130.5% of sales revenue
- Total expenses rose to Rs 232.32 lacs, up from Rs 147.19 lacs in the year-ago quarter
- Earnings Per Share (EPS) turned negative at Rs -0.01 for the quarter
Shree Ganesh Biotech reported a net loss of Rs 0.57 Cr for Q1 FY27, a significant deterioration from a profit of Rs 0.33 Cr in the same quarter last year. Revenue from operations fell 32.6% sequentially to Rs 1.43 Cr from Rs 2.12 Cr in the March 2026 quarter. A critical concern is that cost of materials consumed (Rs 1.87 Cr) alone exceeded the total revenue from operations (Rs 1.43 Cr). With a market cap of only Rs 14 Cr, these losses represent a meaningful erosion of value relative to the company's size.
- Net loss of Rs 57.32 lacs in Q1 FY27 compared to a profit of Rs 32.70 lacs in Q1 FY26
- Revenue from operations declined 32.6% QoQ to Rs 142.99 lacs from Rs 212.13 lacs
- Cost of materials consumed at Rs 186.67 lacs represents 130.5% of revenue from operations
- Total expenses rose to Rs 232.32 lacs, leading to a loss before tax of Rs 57.32 lacs
- Earnings Per Share (EPS) turned negative at Rs (0.01) for the quarter
Shree Ganesh Biotech (India) Ltd has scheduled a board meeting on August 4, 2026, to consider and approve the unaudited financial results for the quarter ended June 30, 2026. This is a routine regulatory filing under SEBI (LODR) Regulations. The company is currently a micro-cap with a market capitalization of ₹14 Cr and has been struggling with profitability, reporting an operating loss of ₹0.43 Cr in the most recent March 2026 quarter. Investors will be monitoring the upcoming results for any signs of recovery in operating margins, which currently stand at -19.5% on a TTM basis.
- Board meeting scheduled for August 4, 2026, to review Q1 FY27 performance.
- Company reported a TTM revenue of ₹5 Cr, which is small relative to its ₹64 Cr net worth.
- Previous quarter (March 2026) saw a net loss of ₹0.15 Cr on revenue of ₹2.12 Cr.
- The stock is currently trading at a low P/B of 0.2, reflecting weak return on capital (ROCE of 0.8%).
Financial Performance
Financial analysis data not yet available for this company.
Operational Drivers
Operational analysis data not yet available for this company.
Strategic Growth
Strategic growth analysis not yet available for this company.
External Factors
External factors analysis not yet available for this company.
Regulatory & Governance
Regulatory analysis not yet available for this company.
Risk Analysis
Risk analysis not yet available for this company.
